Literature DB >> 21743487

The proto-oncogene Pim-1 is a target of miR-33a.

M Thomas1, K Lange-Grünweller, U Weirauch, D Gutsch, A Aigner, A Grünweller, R K Hartmann.   

Abstract

The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR-33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3'-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743487     DOI: 10.1038/onc.2011.278

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

Review 1.  microRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis.

Authors:  Martin Busch; Alma Zernecke
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

2.  miR-146a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium.

Authors:  Yan Huang; Melissa Crawford; Natalia Higuita-Castro; Patrick Nana-Sinkam; Samir N Ghadiali
Journal:  FASEB J       Date:  2012-05-16       Impact factor: 5.191

3.  PEI-complexed LNA antiseeds as miRNA inhibitors.

Authors:  Maren Thomas; Kerstin Lange-Grünweller; Eyas Dayyoub; Udo Bakowsky; Ulrike Weirauch; Achim Aigner; Roland K Hartmann; Arnold Grünweller
Journal:  RNA Biol       Date:  2012-08-01       Impact factor: 4.652

4.  The Mammalian response to virus infection is independent of small RNA silencing.

Authors:  Simone Backes; Ryan A Langlois; Sonja Schmid; Andrew Varble; Jaehee V Shim; David Sachs; Benjamin R tenOever
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

Review 5.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

6.  Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional Mechanisms.

Authors:  Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  J Biol Chem       Date:  2015-03-28       Impact factor: 5.157

7.  MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma.

Authors:  Ru-Ting Xie; Xian-Ling Cong; Xiao-Ming Zhong; Ping Luo; Hui-Qiong Yang; Gai-Xia Lu; Pei Luo; Zheng-Yan Chang; Ran Sun; Ting-Miao Wu; Zhong-Wei Lv; Da Fu; Yu-Shui Ma
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

Review 8.  The plaque "micro" environment: microRNAs control the risk and the development of atherosclerosis.

Authors:  Katey J Rayner; Kathryn J Moore
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

9.  miRNA-Based Therapeutic Strategies.

Authors:  Masaharu Ishida; Florin M Selaru
Journal:  Curr Anesthesiol Rep       Date:  2012-12-24

10.  MicroRNA-33b inhibits tumor cell growth and is associated with prognosis in colorectal cancer patients.

Authors:  W Liao; C Gu; A Huang; J Yao; R Sun
Journal:  Clin Transl Oncol       Date:  2015-09-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.